21 July 2017 in Gastroenterology Report
Variceal bleeding is one of the major causes of death in cirrhotic patients. The management during the acute phase and the secondary prophylaxis is well defined. Recent recommendations (2015 Baveno VI expert consensus) are available and should be followed for an optimal management, which must be performed as an emergency in a liver or general intensive-care unit. It is based on the early administration of a vasoactive drug (before endoscopy), an antibiotic prophylaxis and a restrictive transfusion strategy (hemoglobin target of 7 g/dL). The endoscopic treatment is based on band ligations. Sclerotherapy should be abandoned. In the most severe patients (Child Pugh C or B with active bleeding during initial endoscopy), transjugular intrahepatic portosystemic shunt (TIPS) should be performed within 72 hours after admission to minimize the risk of rebleeding. Secondary prophylaxis is based on the association of non-selective beta-blockers (NSBBs) and repeated band ligations. TIPS should be considered when bleeding reoccurs in spite of a well-conducted secondary prophylaxis or when NSBBs are poorly tolerated. It should also be considered when bleeding is refractory. Liver transplantation should be discussed when bleeding is not controlled after TIPS insertion and in all cases when liver function is deteriorated.
16 May 2023 in Hepatology
Despite the slowly progressive nature of NAFLD, the number of patients with NAFLD-related cirrhosis significantly increased. Although the management of patients with cirrhosis constantly evolves, improving the prognosis of NAFLD cirrhotic patients is challenging because it is situated at the crossroads between the liver, the metabolic and the cardiovascular diseases. Therefore, the therapeutic interventions target the liver but also the associated cardiometabolic conditions and should be adapted accordingly. The objective of the current review is to critically discuss the particularities in the management of patients with NAFLD-related cirrhosis. We relied on the recommendations of the scientific societies and discussed them in the specific context of NAFLD cirrhosis and the surrounding cardiometabolic milieu. Here we covered the following aspects: (1) the weight loss strategies through lifestyle interventions to avoid sarcopenia and improve portal hypertension (PHT); (2) the optimal control of metabolic comorbidities in particular type 2 diabetes aimed to improve cardiovascular morbidity/mortality but also to lower the incidence of cirrhosis related complications; we discussed various aspects related to the safety of the oral antidiabetic drugs in cirrhosis; (3) the challenges in performing bariatric surgery in patients with cirrhosis related to the PHT and the risk of cirrhosis decompensation; (4) the particularities in the diagnosis and management of the PHT and the difficulties in managing patients awaiting for liver transplantation; we underlined (5) the difficulties to develop drug and to conduct clinical trials in patients with NAFLD-related cirrhosis and discussed the emerging options to overcome these obstacles. Export
23 December 2019 in Liver International
Click on the article title to read more.
17 November 2024 in Clinical Immunology
6 July 2026 in Infectious Diseases Now
2 January 2025 in Metabolic Brain Disease
F(for the Brain-Liver Pitié-Salpêtrière Study Group (BLIPS)
for the Brain-Liver Pitié-Salpêtrière Study Group (BLIPS)
+1